STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Alpha-Lipoic Acid (ALA)

Also known as

ALA · α-Lipoic acid · alpha lipoic acid · Thioctic acid · R-ALA · R-lipoic acid · R-(+)-lipoic acid · S-lipoic acid · R,S-lipoic acid (racemic) · d,l-lipoic acid · Na-RALA (sodium R-lipoate) · sodium R-lipoate · Dihydrolipoic acid (DHLA / reduced form) · thioctic acid (EU/clinical synonym)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Niche talk Systemic Oral; IV in clinical settings Antioxidant & metabolic adjacents

Systemic — oral (consumer/research) and clinical IV antioxidant and mitochondrial cofactor with whole-body metabolic and neuropathy talk.

What people say ALA is a non-peptide supplement discussed for burning or tingling nerve symptoms, metabolic health and antioxidant stacks. People compare ordinary racemic ALA with R-ALA and sodium R-lipoate; price and product form are recurring debates. Doses people talk about
Common oral racemic discussion300–600 mg per day

General-supplement and neuropathy discussions; the underlying notes also include lower bottle amounts.

R-ALA forum amounts · separate form100–300 mg per administration

Some reports use once or twice daily; not an equivalent conversion from racemic ALA.

Sodium R-lipoate · forum meal examples200–400 mg before a carb meal

Oral Na-RALA bodybuilding discussion, not a daily total or proof of nutrient partitioning. Some notes split 200 mg before two meals.

Higher oral research amounts1,200–1,800 mg per day

SYDNEY 2 used once-daily oral totals; separate community notes describe divided use. A study amount is not a recommendation to escalate.

These are reported amounts, not a progression or proven form-conversion formula. Higher amounts bring more tolerability concerns.

Half-life & effect duration

Half-life in the body
  • Racemic ALA · oral / IVAbout 25–33 minutes
Felt duration people report
  • One relief accountRelief within 12 hours; symptoms returned the next morning
  • Continued useChanges after 2–3 weeks, or no benefit at 3 weeks
Timing context & sources
How it may feel Some people report less burning or tingling after days or weeks; others notice no benefit. Nausea, heartburn, dizziness or a sulfur-like aftertaste can be more immediate than any symptom improvement.
Cycles people discuss The existing discussion mainly describes ongoing daily use rather than a fixed on/off cycle. People review several weeks of use, longer habits, or pauses to see whether symptoms return; there is no universal washout calendar. Timing Empty-stomach use and taking it with food for nausea are competing practical patterns in the notes. A short plasma half-life does not tell someone when nerve-symptom relief will begin or end. Stacks ALCAR + ALA (classic duo): Acetyl-L-carnitine + ALA for neuropathy / mitochondrial-support threads; ALCAR trial culture often ~1,500–3,000 mg/day while ALA sits ~600 mg — ratios are parallel dosing, not a fixed blend math. Watch for GI effects (most common): Nausea, heartburn, abdominal pain, vomiting, diarrhea — dose-dependent in oral trials (noticeably higher at 1,200–1,800 mg).
Related
NACGlutathioneAcetyl-L-carnitineBenfotiamineCoenzyme Q10

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Roughly half an hour for parent ALA in plasma, in 12 healthy volunteers given racemic ALA.

Reported study-arm means were 25–33 minutes across oral and IV arms. That does not set the duration of nerve-symptom relief or apply automatically to R-ALA products.

Original abstract reviewed, not full tables. HPLC measured parent ALA; metabolites, absorption and systemic bioavailability are distinct. No exact R-ALA or sodium-R-lipoate conversion is inferred.

Felt duration people report

One person reports relief within 12 hours and symptoms returning the next morning. Others describe changes after two or three weeks—or no benefit at three weeks.

Onset, symptom return and weeks of use are different observations. They do not establish one fixed effect duration.

The first account later adds benfotiamine on day four and concerns non-diabetic pain; repeated comments are the same person. Other posters use different products or additional medicines. No universal treatment claim or dose is inferred.

  • ALA: different symptom timelines in first-person reports (opens in a new tab)Necessary-Wealth-415 reply beginning What form of ALA: twelve-hour onset, next-morning return and benfotiamine on day four. Beardopus: fifteen days; somaybemaybenot: two to three weeks; sau_slugger: no improvement at three weeks.Product/form and other medicines differ. Multiple comments by the same person are not independent reports; peer treatment instructions are not adopted.

Other context in this card

What people say 20

  • Burning/tingling anecdotes (non-diabetic): Idiopathic or compression-neuropathy threads report less burning after weeks at ~300–600+ mg; uncontrolled and confounded. forum
  • Bodybuilding / nutrient partitioning: R-ALA or Na-RALA timed before high-carb meals for “shuttling carbs / insulin-mimetic lite” lore — strong forum culture, weak isolated human recomp proof. forum
  • Stack halo problem: Wins often blurred inside ALCAR+ALA, benfotiamine+ALA, multi-B + antioxidant neuropathy blends, or fat-loss multi-stacks. forum
  • Diabetic neuropathy — oral 600 mg/day: Most-cited oral band; multi-week RCTs and meta-analyses report reductions in Total Symptom Score (pain, burning, paresthesia, numbness) that some authors call clinically relevant. trial
  • Oral dose ceiling talk (SYDNEY 2–style): 600 vs 1,200 vs 1,800 mg/day oral over ~5 weeks all improved symptoms vs placebo; 600 mg often matched higher doses on symptoms while higher arms had more nausea/vomiting/vertigo. trial
  • IV neuropathy (ALADIN / meta-analyses): ~600 mg IV daily for ~3 weeks repeatedly associated with significant short-term neuropathic symptom relief; one ALADIN response-rate summary often retold as ~82.5% (600 mg IV) vs ~57.6% placebo for ≥30% TSS improvement. trial
  • IV 100 vs 600 vs 1,200 mg (ALADIN): 600 mg IV was superior to placebo; 1,200 mg did not clearly beat 600 on symptoms and had more adverse events in classic reporting. trial
  • Oral higher-dose culture: 1,200–1,800 mg/day still appears in trials and forums when 600 “wasn’t enough,” but community and trial notes flag more GI burden with limited extra average benefit. trial
  • IV then oral sequences: Some protocols used short IV courses then months of oral ALA; oral follow-through did not always preserve early IV gains in classic long designs. trial
  • Metal-chelation / Nrf2 adjacency: Lab and animal talk on iron/copper chelation and Nrf2 pathway upregulation; consumer “heavy metal detox” claims often outrun human trial evidence. animal
  • Glucose / insulin sensitivity: Oral 600 / 1,200 / 1,800 mg/day for ~4 weeks improved insulin sensitivity ~25% in one type-2 diabetes study with no clear dose ladder above 600; single ~1,000 mg IV infusion historically improved glucose disposal in a small clamp-style trial. trial
  • Glycemic meta signals: Meta-analyses in metabolic populations report modest lowering of fasting glucose, insulin, HOMA-IR, and sometimes HbA1c across ~200–1,800 mg/day bands — effect sizes and study quality vary. trial
  • Null / mixed glycemic note: Not every RCT shows fasting glucose or HOMA-IR wins (e.g. some 600 mg ± vitamin E designs); community often over-claims “blood-sugar drug.” trial
  • Weight: Meta-analyses in higher-BMI cohorts report modest extra loss vs placebo (order of roughly ~0.7–1.3 kg depending on analysis), sometimes stronger at ≤600 mg and shorter (<10 week) windows; waist circumference usually not meaningfully changed. trial
  • Cardiac autonomic neuropathy (CAN): Oral ~800 mg/day for ~4 months improved some heart-rate-variability measures in one diabetic CAN RCT — niche vs peripheral neuropathy volume. trial
  • Training recovery pilots: Small exercise studies discuss ALA around intensive training for muscle-damage / oxidative markers; not a mainstream ergogenic. trial
  • MS / high-dose oral research: 1,200–2,400 mg/day short pilots for tolerability and inflammatory markers; disability outcomes not established as standard care. trial
  • Cognitive / Alzheimer’s open-label: Uncontrolled 600 mg/day add-on series and fish-oil ± ALA pilots — preliminary, not confirmatory. trial
  • Longer oral / NATHAN-class honesty: Multi-year ~600 mg/day oral work (e.g. NATHAN 1–style ~4-year framing) missed some composite primary nerve-impairment/conduction endpoints while secondary impairment measures sometimes favored ALA — often cited as “helps symptoms more than hard structural scores.” trial
  • Antioxidant framing: Fat- and water-soluble radical scavenging; DHLA may regenerate oxidized vitamin C, vitamin E, CoQ10, and glutathione in vitro — in-vivo durability of direct scavenging is debated because plasma peaks are brief. lab

Doses people talk about 21

  • With-food exception: Users with nausea often take with food knowing absorption may drop — trade-off discussed constantly. forum
  • Higher oral research band: ~1,200–1,800 mg/day was used once daily in the five-week SYDNEY 2 trial. Separate community notes describe BID/TID splitting; that was not the SYDNEY 2 schedule. Extra average symptom benefit was limited versus 600 mg, with more nausea/vomiting/vertigo in higher trial arms. trialforum
  • Consumer antioxidant / general band: ~100–600 mg/day oral common on bottles; many general stacks sit ~300–600 mg/day. forum
  • R-ALA example bands (forum): ~100–300 mg R-ALA 1–2×/day for general use; ~300–600 mg/day R-ALA in aggressive neuropathy threads — highly variable and poorly standardized. forum
  • Na-RALA marketing / forum bands: Stabilized sodium R-lipoate commonly discussed ~100–300 mg/day (sometimes ~150–300 mg), with bodybuilding posts also citing ~200–400 mg pre-carb meal; vendor charts vary. forum
  • Racemic vs R cost fight: Racemic is cheaper and matches nearly all outcome trials; R-ALA/Na-RALA cost 2–3×+ per mg with incomplete head-to-head outcome data. forum
  • Start-low community pattern: Often 300 mg/day × days–1 week, then 600 mg if GI OK — especially if history of reflux or sensitive stomach. forum
  • Uncertainty: Racemic mg ≠ R-ALA mg ≠ Na-RALA exposure; polymerized pure R products may under-deliver; brand and salt form matter more than label claims imply. forum
  • Split examples (oral high dose): e.g. 600 mg 2×/day (1,200) or 600 mg 3×/day (1,800); some labels/communities split 600 as 300 mg BID. forum
  • R-ALA community heuristic: Users often run lower labeled mg than racemic (rough “half” or “~50–70% of racemic mg” talk) because only R is endogenous — not a validated conversion formula. forum
  • Bodybuilding carb-timing examples: Forum posts describe ~200–400 mg Na-RALA before one large carb meal, or split ~200 mg before two carb meals — nutrient-partitioning lore, not RCT neuropathy dosing. forum
  • Framing: Ranges below are from trials, monographs, and forum culture for research/education only — not medical advice, not self-treatment protocols. forum
  • Empty-stomach timing (absorption): Commonly ~30 minutes before the first meal (or other meals if split); food lowered peak plasma ~30% and total exposure ~20% in pharmacokinetic work. trial
  • Metabolic / insulin-sensitivity study band: Oral 600, 1,200, or 1,800 mg/day for ~4 weeks in T2D insulin-sensitivity work; 600 often treated as practical ceiling for that endpoint. trial
  • Weight-meta context doses: Trials pooled in weight meta-analyses span roughly hundreds of mg to ~1,800 mg/day; subgroup talk sometimes favors ≤600 mg and shorter windows. trial
  • CAN trial-style: ~800 mg/day oral for ~4 months in one heart-rate-variability study. trial
  • MS pilot-style oral: ~1,200–2,400 mg/day short-term (weeks) in small safety/inflammatory-marker pilots — not standard consumer guidance. trial
  • IV historical extremes: ALADIN also tested 100 mg and 1,200 mg IV arms; 600 mg became the practical sweet spot in retellings. trial
  • Single IV clamp-style: ~1,000 mg IV single infusion appears in older insulin-sensitivity physiology work — not a consumer protocol. trial
  • Upper research exposure notes: Oral ~1,800 mg/day for months and ~1,200 mg/day for years appeared in neuropathy programs without signal of frequent serious AE; short pilot oral ~2,400 mg/day for 2 weeks in MS work; consumer “safe up to ~2,400 mg/day” talk appears in secondary sources — toxicity case reports exist at accidental multi-gram pediatric/adolescent overdoses. trial
  • Oral neuropathy standard: ~600 mg/day racemic ALA is the most-cited effective oral band in DPN literature and product labeling culture. trial

How it may feel 8

  • Days 1–7: Early reports vary: some describe symptom changes within hours or days, while others notice no benefit. GI effects (nausea, heartburn, loose stool) and sulfur-like breath/urine notes can be early feedback; later improvement is not guaranteed. forum
  • Weeks 4–12: Typical consumer “fair trial” for neuropathy or metabolic stacks at ~600 mg oral; glucose-feel anecdotes appear here if at all. forum
  • Months 3–6: Continuous oral habit common in chronic-symptom threads; proof that gains keep climbing is thinner than short RCT windows. forum
  • Hours 0–2: Plasma peak commonly within ~1 hour (often ~30–60 min) on empty stomach; sulfur aftertaste or mild nausea can show same day. trial
  • Week 1 (high oral arms): SYDNEY 2–style reporting noted TSS improvement starting as early as week 1 at 1,800 mg and week 2 at 600–1,200 mg — group averages, not guarantees. trial
  • Weeks 2–3: Classic IV course length (~3 weeks at 600 mg/day) where meta-analyses mark clinically relevant neuropathic pain/TSS drops. trial
  • Weeks 3–5: Common oral RCT checkpoint (e.g. ~5-week 600–1,800 mg protocols) for burning/pain/paresthesia reassessment. trial
  • Years (NATHAN-class): Multi-year daily 600 mg oral studied for disease-course endpoints — secondary impairment measures sometimes better, primary composites mixed. trial

Cycles people discuss 9

  • Default pattern: Daily oral habit — not peptide-style inject pulses or weekly pins. forum
  • Medium oral blocks: ~4–12 weeks common for “did burning improve?” consumer reassessment and many metabolic/weight study windows. forum
  • Time off: Pauses for GI intolerance, cost, travel, pregnancy caution, or to test symptom return — no universal washout standard. forum
  • Symptom-return experiments: Users stop for 1–4 weeks to see if burning returns; pure anecdote on washout timing. anecdote
  • Not a classic on/off cycle compound: Continuous daily use dominates; “8 weeks on / 4 off” charts are minority influencer invention more than trial culture. forum
  • Bodybuilding cut blocks: R-ALA/Na-RALA often run only during high-carb refeed or bulk phases in older forum culture, then dropped — schedule is lifestyle, not PK-driven. forum
  • Short symptom blocks: ~3–5 weeks daily oral mirrors many short DPN RCTs; ~3 weeks mirrors classic IV courses. trial
  • Extended continuous: Months to years of ~600 mg/day in chronic neuropathy and open-label metabolic habits; multi-year RCT safety data exists at 600 mg oral. trial
  • IV then oral: Some clinical research sequences short IV induction then oral maintenance — not a home protocol. trial

Timing 11

  • Daily versus weekly discussion: Once- or twice-daily oral use, rather than weekly peptide-style schedules, appears in the community notes. That is reported practice: short plasma residence alone does not establish an appropriate dosing interval or symptom duration. forum
  • Split-dose discussion: Community notes include 600 mg three-times-daily examples within a 1,800 mg daily total and GI-tolerance reasons for splitting. SYDNEY 2 instead studied once-daily totals. A short plasma window does not prove a split schedule necessary or better; these are reports, not instructions. forumtrial
  • Na-RALA / liquid R claims: Stabilized sodium salt and some liquid R formulations marketed for higher Cmax / better plasma stability vs plain polymer-prone R acid — PK claims vary by product and are not all published as large outcome trials. forum
  • Downstream “feel lag”: Symptom changes track multi-week nerve/metabolic endpoints, not the 30-minute plasma half-life — users judge burning/glucose days–weeks later. forum
  • Plasma peak (Tmax): Often within ~1 hour or less after oral dose; some formulations report Tmax ~50 min class. trial
  • Half-life: Oral plasma t½ commonly cited ~30 minutes (short circulating window); rapid metabolism/excretion of both enantiomers. trial
  • Absorption versus bioavailability: Teichert's human PK abstract describes racemic oral ALA as nearly completely absorbed but about 30% systemically bioavailable because of hepatic extraction. These are different quantities. trial
  • Food effect: Meal co-ingestion cut peak plasma ~30% and total plasma ALA ~20% vs fasting — drives empty-stomach culture. trial
  • R vs S exposure after racemic: Peak R-enantiomer often ~40–50% higher than S after the same racemic dose — differential absorption favoring R. trial
  • Intracellular reduction: ALA rapidly reduced to DHLA in cells; in-vitro work shows DHLA can be exported quickly — free ALA tissue elevation is transient. lab
  • Age/sex PK pilot note: Small human pilot work suggested bioavailability of racemic vs R forms may vary with age and gender — under-discussed in forums. trial

More on what it is 8

  • Why people search it: Diabetic nerve pain/burning, metabolic/insulin-sensitivity stacks, “universal antioxidant that recycles C/E,” and bodybuilding R-ALA / Na-RALA carb-partitioning lore. forum
  • Research lens: Match claims to form (racemic vs R vs Na-RALA), route (oral empty-stomach vs IV clinic), and duration — 3-week IV ALADIN-style wins ≠ multi-year oral NATHAN primary endpoints. forum
  • What it is: Naturally occurring organosulfur compound (thioctic acid); endogenous mitochondrial cofactor for α-ketoacid dehydrogenase complexes; free supplemental ALA is unbound and pharmacologic-dose, not food-bound lipoyllysine. trial
  • R vs racemic (core form fight): Body synthesizes only the R enantiomer; most human trials used 50:50 racemic R,S-ALA; pure R-ALA and Na-RALA are premium labels with stability/bioavailability debates. trial
  • Oxidized vs reduced: ALA (oxidized) ↔ DHLA (reduced); both appear in antioxidant and metal-chelation lab talk; commercial capsules are usually oxidized ALA. trial
  • Evidence posture: Strongest human signal is short-term diabetic neuropathy symptoms (especially IV 600 mg/day × ~3 weeks and oral ~600 mg/day multi-week windows); long-term structural nerve endpoints are mixed. trial
  • What it is not: Not a peptide, not insulin, not a proven fat-burner, not a cure for neuropathy or diabetes, not interchangeable mg-for-mg across racemic vs R-ALA vs Na-RALA. trial
  • Geography note: In Germany, thioctic acid/ALA has long been used/prescribed for diabetic neuropathy; US market is largely OTC supplement + research framing. trial

Stacks 11

  • ALCAR + ALA (classic duo): Acetyl-L-carnitine + ALA for neuropathy / mitochondrial-support threads; ALCAR trial culture often ~1,500–3,000 mg/day while ALA sits ~600 mg — ratios are parallel dosing, not a fixed blend math. forum
  • Retail neuropathy combo example: Products combining ~600 mg ALA with ~300 mg benfotiamine (± ALCAR, NAC, B12) mirror common clinical-adjacent doses discussed for DPN support. forum
  • Benfotiamine + ALA: Fat-soluble thiamine analog + ALA for diabetic-nerve stacks; each has separate trial cultures. forum
  • NAC / GSH adjacency: Multi-antioxidant redox stacks (NAC, glycine, oral GSH debates) frequently add ALA as “recycles glutathione” lore. forum
  • Vitamins C + E: Older antioxidant-recycling cocktails still pair ALA with C and E; modern meta practice questions blanket high-dose E. forum
  • CoQ10 / PQQ: Mitochondrial multi-stacks for energy and aging talk; confounded multi-ingredient designs. forum
  • Metabolic multi-stacks: Berberine, chromium, cinnamon, metformin adjacency — heavy confounds; glucose-lowering additive risk with diabetes meds. forum
  • Biotin awareness (not a synergy stack): High-dose ALA discussed as competing with biotin absorption/status; some users separate biotin or supplement biotin deliberately during long ALA courses. forum
  • Bodybuilding: R-ALA/Na-RALA + carbs / creatine / insulin-mimetic stacks: Older forum stacks with high-GI carbs, sometimes with other “partitioning” agents — evidence quality low. forum
  • What people compare: Racemic ALA vs R-ALA vs Na-RALA on cost-per-effective-exposure; ALA vs ALCAR alone; ALA vs benfotiamine; oral vs clinic IV courses. forum
  • Omega-3 + ALA (cognitive pilots): Fish-oil concentrate ± 600 mg ALA in small Alzheimer’s-function pilots — specialized research stack. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 16

  • Glucose-lowering / hypoglycemia caution: Theoretical and case-discussion additive risk with insulin or oral antidiabetic drugs; community and monographs urge glucose monitoring when stacked with diabetes meds. Separately, EFSA's 2021 review describes insulin autoimmune syndrome after supplemental ALA in susceptible people, including severe hypoglycemia; it could not determine an intake below which that risk is absent. This is not proof that every dizzy or nauseated forum poster has low glucose or IAS. forum
  • Thyroid conversion talk: The older T4→T3 suppression experiment was in rats, not a demonstrated human levothyroxine interaction. Community reports of separating ALA several hours from thyroid hormone are a separate practice, not a spacing interval validated by that experiment. animalforum
  • Biotin interaction: ALA may interfere with intestinal biotin absorption / biotin-dependent pathways; long-term high-dose users discuss biotin co-supplementation or separation. forum
  • Lab interference adjacency: Biotin (sometimes co-taken in B-complexes) can wreck biotin-based immunoassays; ALA itself is less famous for lab wrecking than biotin but sits in the same “supplement labs” caution culture. forum
  • Chemotherapy timing debates: Antioxidant-vs-chemo theoretical conflicts appear in forums; separate literature explores ALA for chemo-neuropathy prevention — timing should stay in oncology supervision, not DIY. forum
  • Not zero risk: ~600 mg/day oral is often well tolerated in trials lasting years, but quality, polypharmacy (especially glucose drugs), thyroid meds, and form/dose still matter. forum
  • GI vs empty-stomach bind: Best absorption empty stomach; worst stomach often empty stomach — users titrate timing, not only mg. forum
  • GI effects (most common): Nausea, heartburn, abdominal pain, vomiting, diarrhea — dose-dependent in oral trials (noticeably higher at 1,200–1,800 mg). trial
  • Vertigo / dizziness: Dose-related in higher oral arms alongside nausea/vomiting. trial
  • Headache: Reported in oral and community use at multi-hundred-mg totals. trial
  • Skin reactions: Rash, hives, itching — among the more frequently listed oral adverse events. trial
  • Malodorous / sulfur urine: Noted especially around ~1,200 mg/day oral class; sulfur breath/aftertaste also common anecdotes. trial
  • IV allergy risk: Rare anaphylactoid/anaphylactic reactions (including severe laryngospasm cases in literature summaries) after IV ALA — clinic setting, not casual. trial
  • Metal chelation / mineral lore: Preclinical chelation of iron/copper/heavy metals fuels detox stacks; unsupervised chelation narratives are a caution, not a proven home protocol. animal
  • Pregnancy / lactation: Limited observational data on continuous 600 mg oral in pregnancy exists in secondary sources; lactation safety not established — research-only posture is strict avoidance without medical oversight. trial
  • Pediatric accidental overdose: Case reports of seizures/acidosis after multi-tablet pediatric ingestion and rare fatal multi-organ failure after extreme intentional overdose — keep away from children; not a toy antioxidant. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →